IW 379

June 28, 2026 Viktor Zarev 0 min read
  1. GLP-1 drugs drive U.S. healthcare spending over $6T.
  2. Over 11k bottles of blood pressure medication recalled.
  3. Opioid settlement money pays for rural health addiction services. 
  4. Kaiser ordered to pay $82M for out-of-network underpayments. 
  5. Democrats propose capping Medicare out-of-pocket spending. 
  6. How private equity squeezes profit out of hospital patients. 
  7. Project erases $170M in medical debt for 140k Mass. residents. 
  8. Why connecting wearables to medical records might not be a good idea.
  9. Questions over who got early access to experimental obesity drug.
  10. Illinois neurosurgeons accused of leaving patients under anesthesia.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Heart Failure July 4, 2000

How Earlier Hemodynamic Insight May Help Guide Heart Failure Management July 4, 2000

Heart failure continues to place a significant burden on patients and the healthcare system, with nearly 7 million Americans living with heart failure, with prevalence expected to reach nearly 9 million by 2030. Despite advances in guideline-directed medical therapy (GDMT), many patients still face high risks of hospitalization, mortality, and reduced quality of life.

Cardiology Pharmaceuticals July 17, 2026

Can Kerendia Handle the (Blood) Pressure? More Findings from FINEARTS-HF. July 17, 2026

One year after its FDA approval for HF treatment, a new FINEARTS-HF substudy shows Bayer’s Kerendia (finerenone) isn’t just impervious to BP differences, it could actually give a small leg up to patients with hypertension.

Cardiac Imaging July 16, 2026

Zero CAC And The Cost of CCTA-QPA July 16, 2026

The power of a zero CAC score is facing fresh scrutiny after new plaque analysis data presented at SCCT 2026 shows just how much noncalcified plaque confers its own cardiovascular risk, despite the software’s financial barriers.